Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010–2015

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
   PubMed Web of Science ®Google Scholar
• Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149:1295–1299.
   PubMed Web of Science ®Google Scholar
• Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857–866.
   PubMed Web of Science ®Google Scholar
• Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113:5064–5073.
   PubMed Web of Science ®Google Scholar
• Imam MH, Shenoy PJ, Flowers CR, et al. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. 2013;54:752–759.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, et al. NCCN clinical practice guidelines in oncology, non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2010;8:288–334.
   PubMed Web of Science ®Google Scholar
• Arora S, Setia R. Extracorporeal photopheresis: Review of technical aspects. Asian J Transfus Sci. 2017;11:81–86.
   PubMedGoogle Scholar
• Bladon J, Taylor PC. Extracorporeal photopheresis induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and graft-versus-host disease patients. Br J Haematol. 1999;107:707–711.
   PubMed Web of Science ®Google Scholar
• Goussetis E, Varela I, Tsirigotis P. Update on the mechanism of action and on clinical efficacy of extracorporeal photopheresis in the treatment of acute and chronic graft versus host disease in children. Transfus Apher Sci. 2012;46:203–209.
   PubMed Web of Science ®Google Scholar
• Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher. 2006;21:72–77.
   PubMed Web of Science ®Google Scholar
• Hart JW, Shiue LH, Shpall EJ, et al. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Ther Adv Hematol. 2013;4:320–334.
   PubMedGoogle Scholar
• Zic JA. Photopheresis in the treatment of cutaneous T-cell lymphoma: current status. Curr Opin Oncol. 2012;24:S1–S10.
   PubMed Web of Science ®Google Scholar
• Dippel E, Schrag H, Goerdt S, et al. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet. 1997;350:32–33.
   PubMed Web of Science ®Google Scholar
• Alfred A, Taylor PC, Dignan F, et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol. 2017;177:287–310.
   PubMed Web of Science ®Google Scholar
• Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28:1–37.
   PubMed Web of Science ®Google Scholar
• Dunbar NM, Raval JS, Johnson A, et al. Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. J Clin Apheresis. 2017;32:215–223.
   PubMed Web of Science ®Google Scholar
• Ratcliffe N, Dunbar NM, Adamski J, et al. National Institutes of Health state of the science symposium in therapeutic apheresis: scientific opportunities in extracorporeal photopheresis. Transfus Med Rev. 2015;29:62–70.
   Web of Science ®Google Scholar
• Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice–evidence based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue.J Clin Apher.2016;31:149–338.
   Web of Science ®Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Statist Med. 2009;28:3083–3107.
   PubMed Web of Science ®Google Scholar
• Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–615.
   PubMed Web of Science ®Google Scholar
• Wu PA, Kim YH, Lavori PW, et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transplant. 2009;15:982–990.
   PubMed Web of Science ®Google Scholar
• Sanyal S, Child F, Alfred A, et al. UK national audit of extracorporeal photopheresis in cutaneous T‐cell lymphoma. Br J Dermatol. 2018;178:569–570.
   PubMed Web of Science ®Google Scholar
• Lustberg MB. Management of neutropenia in cancer patients. Clin Adv Hematol Oncol. 2012;10:825–826.
   PubMedGoogle Scholar
• Phillips R, Hancock B, Graham J, et al. Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance. BMJ. 2012;345:e5368.
   PubMedGoogle Scholar
• Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453.
   PubMed Web of Science ®Google Scholar
• Gu T, Raspa S, Tsang Y, et al. The burden of illness of mycosis fungoides cutaneous T-Cell lymphoma: a retrospective cohort study of a commercially insured population in the US. Value Health. 2016;19:A608.
   Web of Science ®Google Scholar
• Tsang Y, Gu T, Sharma G, et al. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. J Dermatolog Treat. 2018;29:747–753.
   PubMed Web of Science ®Google Scholar